TSHA Logo

Taysha Gene Therapies, Inc. (TSHA) 

NASDAQ
Market Cap
$275.65M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
67 of 776
Rank in Industry
54 of 433

Largest Insider Buys in Sector

TSHA Stock Price History Chart

TSHA Stock Performance

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, …

Insider Activity of Taysha Gene Therapies, Inc.

Over the last 12 months, insiders at Taysha Gene Therapies, Inc. have bought $3.16M and sold $0 worth of Taysha Gene Therapies, Inc. stock.

On average, over the past 5 years, insiders at Taysha Gene Therapies, Inc. have bought $6.24M and sold $975,279 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Manning Paul B (10 percent owner) — $15.81M.

The last purchase of 1,333,333 shares for transaction amount of $3M was made by Manning Paul B (10 percent owner) on 2024‑06‑27.

List of Insider Buy and Sell Transactions, Taysha Gene Therapies, Inc.

2024-06-27Purchase10 percent owner
1.33M
0.7863%
$2.25$3M0.00%
2023-11-17Purchase10 percent owner
100,000
0.0519%
$1.63$163,000+29.34%
2023-08-24SaleChief Financial Officer
33,000
0.0537%
$2.33$76,890+0.43%
2023-08-16Purchase10 percent owner
16.47M
11.9647%
$0.90$14.82M+21.50%
2023-08-16PurchaseChief Executive Officer
444,444
0.3229%
$0.90$400,000+21.50%
2023-08-16Purchasedirector
777,778
0.5651%
$0.90$700,000+21.50%
2023-08-16Purchasedirector
111,111
0.0807%
$0.90$100,000+21.50%
2023-07-13Sale10 percent owner
5,344
0.0084%
$0.70$3,741+232.86%
2023-07-12Sale10 percent owner
80,528
0.1263%
$0.71$57,030+224.23%
2023-06-23Sale10 percent owner
18,100
0.0305%
$0.70$12,735+242.42%
2023-06-22Sale10 percent owner
10,508
0.0163%
$0.70$7,384+214.94%
2023-06-21Sale10 percent owner
138,962
0.2204%
$0.70$97,635+221.43%
2023-06-20Sale10 percent owner
295,653
0.4778%
$0.71$210,209+223.74%
2023-05-16PurchasePresident and Head of R&D
5,000
0.0078%
$0.68$3,400+173.12%
2022-10-31Purchasedirector
1.5M
3.9684%
$2.00$3M-34.88%
2022-08-23SaleChief Financial Officer
3,325
0.0081%
$3.47$11,538-67.72%
2022-08-18SaleChief Financial Officer
11,482
0.0271%
$3.75$43,058-71.13%
2022-07-05SaleCMO and Head of R&D
3,905
0.0095%
$3.51$13,707-48.86%
2022-06-29SaleCMO and Head of R&D
12,324
0.0304%
$3.81$46,954-51.95%
2022-02-03Purchase
76,602
0.2022%
$7.84$600,560-59.00%

Insider Historical Profitability

<0.0001%
Manning Paul B10 percent owner
1333333
0.6506%
$1.3590<0.0001%
Session R.A. II10 percent owner
8871747
4.3289%
$1.3516<0.0001%
Nolan Sean P.Chief Executive Officer
1535545
0.7493%
$1.3520<0.0001%
Stalfort John A IIIdirector
999381
0.4876%
$1.3510
Donenberg Phillip B.director
114111
0.0557%
$1.3520<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$57.72M9.9920.11M-10.38%-$6.68M<0.01
Avoro Capital Advisors Llc$53.53M9.2618.65M+328.19%+$41.03M0.64
RTW Investments, LP$53.36M9.2318.59M+10.06%+$4.88M0.8
RA Capital Management, L.P.$31.2M5.410.87M-41.14%-$21.81M0.03
Vr Adviser Llc$25.83M4.479M-13.57%-$4.05M1.26
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.